{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:04:25Z","timestamp":1790521465831,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Research, Development and Innovation Office","award":["FIEK 16-1-2016-0005 and VEKOP-2.1.1-15-2016-00117"],"award-info":[{"award-number":["FIEK 16-1-2016-0005 and VEKOP-2.1.1-15-2016-00117"]}]},{"name":"National Research, Development and Innovation Office","award":["FK 128751"],"award-info":[{"award-number":["FK 128751"]}]},{"name":"National Research, Development and Innovation Office","award":["KFI_16-1-2017-0232"],"award-info":[{"award-number":["KFI_16-1-2017-0232"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Transporters in the human liver play a major role in the clearance of endo- and xenobiotics. Apical (canalicular) transporters extrude compounds to the bile, while basolateral hepatocyte transporters promote the uptake of, or expel, various compounds from\/into the venous blood stream. In the present work we have examined the in vitro interactions of some key repurposed drugs advocated to treat COVID-19 (lopinavir, ritonavir, ivermectin, remdesivir and favipiravir), with the key drug transporters of hepatocytes. These transporters included ABCB11\/BSEP, ABCC2\/MRP2, and SLC47A1\/MATE1 in the canalicular membrane, as well as ABCC3\/MRP3, ABCC4\/MRP4, SLC22A1\/OCT1, SLCO1B1\/OATP1B1, SLCO1B3\/OATP1B3, and SLC10A1\/NTCP, residing in the basolateral membrane. Lopinavir and ritonavir in low micromolar concentrations inhibited BSEP and MATE1 exporters, as well as OATP1B1\/1B3 uptake transporters. Ritonavir had a similar inhibitory pattern, also inhibiting OCT1. Remdesivir strongly inhibited MRP4, OATP1B1\/1B3, MATE1 and OCT1. Favipiravir had no significant effect on any of these transporters. Since both general drug metabolism and drug-induced liver toxicity are strongly dependent on the functioning of these transporters, the various interactions reported here may have important clinical relevance in the drug treatment of this viral disease and the existing co-morbidities.<\/jats:p>","DOI":"10.1038\/s41598-021-97160-3","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T10:02:46Z","timestamp":1631095366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics"],"prefix":"10.1038","volume":"11","author":[{"given":"Csilla","family":"Ambrus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va","family":"Bakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Sarkadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csilla","family":"\u00d6zvegy-Laczka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes","family":"Telbisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,8]]},"reference":[{"key":"97160_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104787","volume":"178","author":"L Caly","year":"2020","unstructured":"Caly, L., Druce, J. D., Catton, M. G., Jans, D. A. & Wagstaff, K. M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 178, 104787. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104787 (2020).","journal-title":"Antiviral Res."},{"key":"97160_CR2","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1177\/009127002401382731","volume":"42","author":"CA Guzzo","year":"2002","unstructured":"Guzzo, C. A. et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J. Clin. Pharmacol. 42, 1122\u20131133. https:\/\/doi.org\/10.1177\/009127002401382731 (2002).","journal-title":"J. Clin. Pharmacol."},{"key":"97160_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2020-001350","author":"JJ DiNicolantonio","year":"2020","unstructured":"DiNicolantonio, J. J., Barroso, J. & McCarty, M. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. Open Heart. https:\/\/doi.org\/10.1136\/openhrt-2020-001350 (2020).","journal-title":"Open Heart."},{"key":"97160_CR4","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.2020.6019","volume":"323","author":"JM Sanders","year":"2020","unstructured":"Sanders, J. M., Monogue, M. L., Jodlowski, T. Z. & Cutrell, J. B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA 323, 1824\u20131836. https:\/\/doi.org\/10.1001\/jama.2020.6019 (2020).","journal-title":"JAMA"},{"key":"97160_CR5","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao, B. et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med. 382, 1787\u20131799. https:\/\/doi.org\/10.1056\/NEJMoa2001282 (2020).","journal-title":"N. Engl. J. Med."},{"key":"97160_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104786","volume":"178","author":"KT Choy","year":"2020","unstructured":"Choy, K. T. et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 178, 104786. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104786 (2020).","journal-title":"Antiviral Res."},{"key":"97160_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269\u2013271. https:\/\/doi.org\/10.1038\/s41422-020-0282-0 (2020).","journal-title":"Cell Res."},{"key":"97160_CR8","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of Covid-19\u2014Final report. N. Engl. J. Med. 383, 1813\u20131826. https:\/\/doi.org\/10.1056\/NEJMoa2007764 (2020).","journal-title":"N. Engl. J. Med."},{"key":"97160_CR9","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","volume":"383","author":"JD Goldman","year":"2020","unstructured":"Goldman, J. D. et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N. Engl. J. Med. 383, 1827\u20131837. https:\/\/doi.org\/10.1056\/NEJMoa2015301 (2020).","journal-title":"N. Engl. J. Med."},{"key":"97160_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0242184","volume":"15","author":"D Camprubi","year":"2020","unstructured":"Camprubi, D. et al. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PLoS ONE 15, e0242184. https:\/\/doi.org\/10.1371\/journal.pone.0242184 (2020).","journal-title":"PLoS ONE"},{"key":"97160_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100720","volume":"32","author":"C Chaccour","year":"2021","unstructured":"Chaccour, C. et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 32, 100720. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100720 (2021).","journal-title":"EClinicalMedicine"},{"key":"97160_CR12","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3904\/kjim.2020.157","volume":"35","author":"CK Kang","year":"2020","unstructured":"Kang, C. K. et al. In vitro activity of lopinavir\/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses. Korean J. Intern. Med. 35, 782\u2013787. https:\/\/doi.org\/10.3904\/kjim.2020.157 (2020).","journal-title":"Korean J. Intern. Med."},{"key":"97160_CR13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"H Pan","year":"2021","unstructured":"Pan, H. et al. Repurposed antiviral drugs for Covid-19\u2014Interim WHO solidarity trial results. N. Engl. J. Med. 384, 497\u2013511. https:\/\/doi.org\/10.1056\/NEJMoa2023184 (2021).","journal-title":"N. Engl. J. Med."},{"key":"97160_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ph14060520","author":"AM Heustess","year":"2021","unstructured":"Heustess, A. M., Allard, M. A., Thompson, D. K. & Fasinu, P. S. Clinical management of COVID-19: A review of pharmacological treatment options. Pharmaceuticals (Basel, Switzerland). https:\/\/doi.org\/10.3390\/ph14060520 (2021).","journal-title":"Pharmaceuticals (Basel, Switzerland)."},{"key":"97160_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1124\/pr.118.015578","volume":"72","author":"H Koepsell","year":"2020","unstructured":"Koepsell, H. Organic cation transporters in health and disease. Pharmacol. Rev. 72, 253\u2013319. https:\/\/doi.org\/10.1124\/pr.118.015578 (2020).","journal-title":"Pharmacol. Rev."},{"key":"97160_CR16","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1111\/j.1476-5381.2011.01394.x","volume":"164","author":"A Yonezawa","year":"2011","unstructured":"Yonezawa, A. & Inui, K. Importance of the multidrug and toxin extrusion MATE\/SLC47A family to pharmacokinetics, pharmacodynamics\/toxicodynamics and pharmacogenomics. Br. J. Pharmacol. 164, 1817\u20131825. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01394.x (2011).","journal-title":"Br. J. Pharmacol."},{"key":"97160_CR17","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/toxsci\/kft197","volume":"136","author":"JM Pedersen","year":"2013","unstructured":"Pedersen, J. M. et al. Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP\/ABCB11). Toxicol. Sci. 136, 328\u2013343. https:\/\/doi.org\/10.1093\/toxsci\/kft197 (2013).","journal-title":"Toxicol. Sci."},{"key":"97160_CR18","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1124\/dmd.111.041731","volume":"40","author":"DR de Waart","year":"2012","unstructured":"de Waart, D. R. et al. Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab. Dispos. 40, 515\u2013521. https:\/\/doi.org\/10.1124\/dmd.111.041731 (2012).","journal-title":"Drug Metab. Dispos."},{"key":"97160_CR19","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jhep.2005.07.022","volume":"44","author":"N Zelcer","year":"2006","unstructured":"Zelcer, N. et al. Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J. Hepatol. 44, 768\u2013775. https:\/\/doi.org\/10.1016\/j.jhep.2005.07.022 (2006).","journal-title":"J. Hepatol."},{"key":"97160_CR20","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1016\/j.xphs.2017.04.040","volume":"106","author":"K Kanamitsu","year":"2017","unstructured":"Kanamitsu, K., Kusuhara, H., Schuetz, J. D., Takeuchi, K. & Sugiyama, Y. Investigation of the importance of multidrug resistance-associated protein 4 (Mrp4\/Abcc4) in the active efflux of anionic drugs across the blood-brain barrier. J. Pharm. Sci. 106, 2566\u20132575. https:\/\/doi.org\/10.1016\/j.xphs.2017.04.040 (2017).","journal-title":"J. Pharm. Sci."},{"key":"97160_CR21","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1124\/mol.63.5.1094","volume":"63","author":"G Reid","year":"2003","unstructured":"Reid, G. et al. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol. Pharmacol. 63, 1094\u20131103. https:\/\/doi.org\/10.1124\/mol.63.5.1094 (2003).","journal-title":"Mol. Pharmacol."},{"key":"97160_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1081\/dmr-200047984","volume":"37","author":"CA Ritter","year":"2005","unstructured":"Ritter, C. A. et al. Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab. Rev. 37, 253\u2013278. https:\/\/doi.org\/10.1081\/dmr-200047984 (2005).","journal-title":"Drug Metab. Rev."},{"key":"97160_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.tips.2008.01.006","volume":"29","author":"FG Russel","year":"2008","unstructured":"Russel, F. G., Koenderink, J. B. & Masereeuw, R. Multidrug resistance protein 4 (MRP4\/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol. Sci. 29, 200\u2013207. https:\/\/doi.org\/10.1016\/j.tips.2008.01.006 (2008).","journal-title":"Trends Pharmacol. Sci."},{"key":"97160_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/B978-0-12-394316-3.00004-1","volume":"70","author":"B Doring","year":"2012","unstructured":"Doring, B., Lutteke, T., Geyer, J. & Petzinger, E. The SLC10 carrier family: transport functions and molecular structure. Curr. Top. Membr. 70, 105\u2013168. https:\/\/doi.org\/10.1016\/B978-0-12-394316-3.00004-1 (2012).","journal-title":"Curr. Top. Membr."},{"key":"97160_CR25","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1053\/j.gastro.2006.02.034","volume":"130","author":"RH Ho","year":"2006","unstructured":"Ho, R. H. et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130, 1793\u20131806. https:\/\/doi.org\/10.1053\/j.gastro.2006.02.034 (2006).","journal-title":"Gastroenterology"},{"key":"97160_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40262-013-0097-y","volume":"53","author":"M Jamei","year":"2014","unstructured":"Jamei, M. et al. A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. Clin. Pharmacokinet. 53, 73\u201387. https:\/\/doi.org\/10.1007\/s40262-013-0097-y (2014).","journal-title":"Clin. Pharmacokinet."},{"key":"97160_CR27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/17425255.2017.1253679","volume":"13","author":"D Kovacsics","year":"2017","unstructured":"Kovacsics, D., Patik, I. & Ozvegy-Laczka, C. The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions. Expert Opin. Drug Metab. Toxicol. 13, 409\u2013424. https:\/\/doi.org\/10.1080\/17425255.2017.1253679 (2017).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"97160_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1248\/bpb.b14-00767","volume":"38","author":"K Maeda","year":"2015","unstructured":"Maeda, K. Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs. Biol. Pharm. Bull. 38, 155\u2013168. https:\/\/doi.org\/10.1248\/bpb.b14-00767 (2015).","journal-title":"Biol. Pharm. Bull."},{"key":"97160_CR29","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1124\/mol.118.114314","volume":"95","author":"RR Schulte","year":"2019","unstructured":"Schulte, R. R. & Ho, R. H. Organic anion transporting polypeptides: emerging roles in cancer pharmacology. Mol. Pharmacol. 95, 490\u2013506. https:\/\/doi.org\/10.1124\/mol.118.114314 (2019).","journal-title":"Mol. Pharmacol."},{"key":"97160_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12090856","author":"DA Garrison","year":"2020","unstructured":"Garrison, D. A., Talebi, Z., Eisenmann, E. D., Sparreboom, A. & Baker, S. D. Role of OATP1B1 and OATP1B3 in drug-drug interactions mediated by tyrosine kinase inhibitors. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics12090856 (2020).","journal-title":"Pharmaceutics"},{"key":"97160_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13010081","author":"A Telbisz","year":"2021","unstructured":"Telbisz, A. et al. Interactions of potential anti-COVID-19 compounds with multispecific ABC and OATP drug transporters. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics13010081 (2021).","journal-title":"Pharmaceutics"},{"key":"97160_CR32","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.febslet.2005.12.039","volume":"580","author":"P Borst","year":"2006","unstructured":"Borst, P., Zelcer, N., van de Wetering, K. & Poolman, B. On the putative co-transport of drugs by multidrug resistance proteins. FEBS Lett. 580, 1085\u20131093. https:\/\/doi.org\/10.1016\/j.febslet.2005.12.039 (2006).","journal-title":"FEBS Lett."},{"key":"97160_CR33","doi-asserted-by":"publisher","first-page":"23529","DOI":"10.1074\/jbc.M303515200","volume":"278","author":"A Bodo","year":"2003","unstructured":"Bodo, A., Bakos, E., Szeri, F., Varadi, A. & Sarkadi, B. Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J. Biol. Chem. 278, 23529\u201323537. https:\/\/doi.org\/10.1074\/jbc.M303515200 (2003).","journal-title":"J. Biol. Chem."},{"key":"97160_CR34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3028","volume":"9","author":"International Transporter C","year":"2010","unstructured":"International Transporter C et al. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9, 215\u2013236. https:\/\/doi.org\/10.1038\/nrd3028 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"97160_CR35","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/0092-8674(94)90212-7","volume":"77","author":"AH Schinkel","year":"1994","unstructured":"Schinkel, A. H. et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491\u2013502. https:\/\/doi.org\/10.1016\/0092-8674(94)90212-7 (1994).","journal-title":"Cell"},{"key":"97160_CR36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/jps.22262","volume":"100","author":"M Jani","year":"2011","unstructured":"Jani, M. et al. Ivermectin interacts with human ABCG2. J. Pharm. Sci. 100, 94\u201397. https:\/\/doi.org\/10.1002\/jps.22262 (2011).","journal-title":"J. Pharm. Sci."},{"key":"97160_CR37","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cbi.2005.11.002","volume":"159","author":"A Lespine","year":"2006","unstructured":"Lespine, A. et al. Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3). Chem. Biol. Interact. 159, 169\u2013179. https:\/\/doi.org\/10.1016\/j.cbi.2005.11.002 (2006).","journal-title":"Chem. Biol. Interact."},{"key":"97160_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/s0006-2952(96)00656-9","volume":"53","author":"JF Pouliot","year":"1997","unstructured":"Pouliot, J. F., L\u2019Heureux, F., Liu, Z., Prichard, R. K. & Georges, E. Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem. Pharmacol. 53, 17\u201325. https:\/\/doi.org\/10.1016\/s0006-2952(96)00656-9 (1997).","journal-title":"Biochem. Pharmacol."},{"key":"97160_CR39","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/00001813-199609000-00005","volume":"7","author":"A Didier","year":"1996","unstructured":"Didier, A. & Loor, F. The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor. Anticancer Drugs 7, 745\u2013751. https:\/\/doi.org\/10.1097\/00001813-199609000-00005 (1996).","journal-title":"Anticancer Drugs"},{"key":"97160_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ijpharm.2007.02.036","volume":"339","author":"S Agarwal","year":"2007","unstructured":"Agarwal, S., Pal, D. & Mitra, A. K. Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int. J. Pharm. 339, 139\u2013147. https:\/\/doi.org\/10.1016\/j.ijpharm.2007.02.036 (2007).","journal-title":"Int. J. Pharm."},{"key":"97160_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3109\/00498250903509375","volume":"40","author":"P Annaert","year":"2010","unstructured":"Annaert, P., Ye, Z. W., Stieger, B. & Augustijns, P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 40, 163\u2013176. https:\/\/doi.org\/10.3109\/00498250903509375 (2010).","journal-title":"Xenobiotica"},{"key":"97160_CR42","first-page":"866","volume":"27","author":"M Cvetkovic","year":"1999","unstructured":"Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R. & Kim, R. B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27, 866\u2013871 (1999).","journal-title":"Drug Metab. Dispos."},{"key":"97160_CR43","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1124\/jpet.104.065342","volume":"310","author":"A Gupta","year":"2004","unstructured":"Gupta, A., Zhang, Y., Unadkat, J. D. & Mao, Q. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP\/ABCG2). J. Pharmacol. Exp. Ther. 310, 334\u2013341. https:\/\/doi.org\/10.1124\/jpet.104.065342 (2004).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"97160_CR44","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1097\/00002030-200211220-00009","volume":"16","author":"MT Huisman","year":"2002","unstructured":"Huisman, M. T. et al. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS (London, England) 16, 2295\u20132301. https:\/\/doi.org\/10.1097\/00002030-200211220-00009 (2002).","journal-title":"AIDS (London, England)"},{"key":"97160_CR45","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jps.1133","volume":"90","author":"MD Perloff","year":"2001","unstructured":"Perloff, M. D., Von Moltke, L. L., Marchand, J. E. & Greenblatt, D. J. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J. Pharm. Sci. 90, 1829\u20131837. https:\/\/doi.org\/10.1002\/jps.1133 (2001).","journal-title":"J. Pharm. Sci."},{"key":"97160_CR46","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/bcp.14489","volume":"87","author":"B Batteux","year":"2021","unstructured":"Batteux, B. et al. Abnormal laboratory findings and plasma concentration monitoring of lopinavir and ritonavir in COVID-19. Br. J. Clin. Pharmacol. 87, 1547\u20131553. https:\/\/doi.org\/10.1111\/bcp.14489 (2021).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"97160_CR47","unstructured":"In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (National Institute of Diabetes and Digestive and Kidney Diseases, 2012). PMID: 31643176, Bookshelf ID: NBK547852"},{"key":"97160_CR48","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1124\/dmd.113.054304","volume":"42","author":"K K\u00f6ck","year":"2014","unstructured":"K\u00f6ck, K. et al. Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab. Dispos. 42, 665\u2013674. https:\/\/doi.org\/10.1124\/dmd.113.054304 (2014).","journal-title":"Drug Metab. Dispos."},{"key":"97160_CR49","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.clpt.2005.01.018","volume":"77","author":"M Niemi","year":"2005","unstructured":"Niemi, M. et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther. 77, 468\u2013478. https:\/\/doi.org\/10.1016\/j.clpt.2005.01.018 (2005).","journal-title":"Clin. Pharmacol. Ther."},{"key":"97160_CR50","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","volume":"158","author":"A Kalliokoski","year":"2009","unstructured":"Kalliokoski, A. & Niemi, M. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol. 158, 693\u2013705. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00430.x (2009).","journal-title":"Br. J. Pharmacol."},{"key":"97160_CR51","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.xphs.2017.04.078","volume":"106","author":"X Liang","year":"2017","unstructured":"Liang, X. & Giacomini, K. M. Transporters involved in metformin pharmacokinetics and treatment response. J. Pharm. Sci. 106, 2245\u20132250. https:\/\/doi.org\/10.1016\/j.xphs.2017.04.078 (2017).","journal-title":"J. Pharm. Sci."},{"key":"97160_CR52","doi-asserted-by":"publisher","first-page":"20958","DOI":"10.1038\/s41598-020-78029-3","volume":"10","author":"J Mac\u00edas","year":"2020","unstructured":"Mac\u00edas, J. et al. High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment. Sci. Rep. 10, 20958. https:\/\/doi.org\/10.1038\/s41598-020-78029-3 (2020).","journal-title":"Sci. Rep."},{"key":"97160_CR53","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/phar.2429","volume":"40","author":"SCJ Jorgensen","year":"2020","unstructured":"Jorgensen, S. C. J., Kebriaei, R. & Dresser, L. D. Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Pharmacotherapy 40, 659\u2013671. https:\/\/doi.org\/10.1002\/phar.2429 (2020).","journal-title":"Pharmacotherapy"},{"key":"97160_CR54","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1124\/jpet.115.225656","volume":"354","author":"J Wen","year":"2015","unstructured":"Wen, J. et al. The pharmacological and physiological role of multidrug-resistant protein 4. J. Pharmacol. Exp. Ther. 354, 358\u2013375. https:\/\/doi.org\/10.1124\/jpet.115.225656 (2015).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"97160_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225702","volume":"14","author":"X Zhao","year":"2019","unstructured":"Zhao, X. et al. Involvement of human and canine MRP1 and MRP4 in benzylpenicillin transport. PLoS ONE 14, e0225702. https:\/\/doi.org\/10.1371\/journal.pone.0225702 (2019).","journal-title":"PLoS ONE"},{"key":"97160_CR56","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.2174\/092986708785132870","volume":"15","author":"SF Zhou","year":"2008","unstructured":"Zhou, S. F. et al. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr. Med. Chem. 15, 1981\u20132039. https:\/\/doi.org\/10.2174\/092986708785132870 (2008).","journal-title":"Curr. Med. Chem."},{"key":"97160_CR57","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1158\/1078-0432.CCR-13-0980","volume":"19","author":"BD Furmanski","year":"2013","unstructured":"Furmanski, B. D. et al. Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib. Clin. Cancer Res. 19, 4359\u20134370. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0980 (2013).","journal-title":"Clin. Cancer Res."},{"key":"97160_CR58","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/sj.clpt.6100269","volume":"83","author":"JJ Kiser","year":"2008","unstructured":"Kiser, J. J. et al. The effect of lopinavir\/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin. Pharmacol. Ther. 83, 265\u2013272. https:\/\/doi.org\/10.1038\/sj.clpt.6100269 (2008).","journal-title":"Clin. Pharmacol. Ther."},{"key":"97160_CR59","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1038\/s41598-018-20815-1","volume":"8","author":"I Patik","year":"2018","unstructured":"Patik, I. et al. Identification of novel cell-impermeant fluorescent substrates for testing the function and drug interaction of Organic Anion-Transporting Polypeptides, OATP1B1\/1B3 and 2B1. Sci. Rep. 8, 2630. https:\/\/doi.org\/10.1038\/s41598-018-20815-1 (2018).","journal-title":"Sci. Rep."},{"key":"97160_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105395","volume":"151","author":"V Szekely","year":"2020","unstructured":"Szekely, V. et al. Fluorescent probes for the dual investigation of MRP2 and OATP1B1 function and drug interactions. Eur. J. Pharm. Sci. 151, 105395. https:\/\/doi.org\/10.1016\/j.ejps.2020.105395 (2020).","journal-title":"Eur. J. Pharm. Sci."},{"key":"97160_CR61","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1124\/dmd.118.085993","volume":"47","author":"P Tatrai","year":"2019","unstructured":"Tatrai, P. et al. A systematic in vitro investigation of the inhibitor preincubation effect on multiple classes of clinically relevant transporters. Drug Metab. Dispos. 47, 768\u2013778. https:\/\/doi.org\/10.1124\/dmd.118.085993 (2019).","journal-title":"Drug Metab. Dispos."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97160-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97160-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97160-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T15:27:14Z","timestamp":1670081234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97160-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["97160"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-97160-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,8]]},"assertion":[{"value":"1 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17810"}}